The state of testosterone therapy since the FDA's 2015 labelling changes: Indications and cardiovascular risk.

We conclude that existing evidence fails to support increased CV risk with TTh; on the contrary, there is evidence suggestive of real-world CV benefits. Finally, existing evidence provides benefits of TTh in older men without known aetiology for T deficiency.